NASDAQ:JBIO Jade Biosciences (JBIO) Stock Price, News & Analysis $21.04 +0.20 (+0.96%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$21.61 +0.57 (+2.71%) As of 05/29/2026 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jade Biosciences Stock (NASDAQ:JBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jade Biosciences alerts:Sign Up Key Stats Today's Range$20.42▼$21.6750-Day Range$13.26▼$26.8552-Week Range$6.57▼$28.00Volume1.12 million shsAverage Volume455,524 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$34.33Consensus RatingModerate Buy Company Overview Jade Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments. The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications. Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets. AI Generated. May Contain Errors. Read More Jade Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreJBIO MarketRank™: Jade Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 630th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingJade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialJade Biosciences has a consensus price target of $34.33, representing about 63.2% upside from its current price of $21.04.Amount of Analyst CoverageJade Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jade Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jade Biosciences are expected to decrease in the coming year, from ($2.43) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jade Biosciences is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jade Biosciences is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJade Biosciences has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.95% of the float of Jade Biosciences has been sold short.Short Interest Ratio / Days to CoverJade Biosciences has a short interest ratio ("days to cover") of 7.66.Change versus previous monthShort interest in Jade Biosciences has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJade Biosciences does not currently pay a dividend.Dividend GrowthJade Biosciences does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News SentimentJade Biosciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Jade Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for JBIO on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jade Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsJade Biosciences has minimal institutional ownership at this time.Read more about Jade Biosciences' insider trading history. Receive JBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBIO Stock News HeadlinesJade Biosciences to Host Conference Call on Phase 1 Study Results of JADE101 for Immunoglobulin A NephropathyMay 29 at 4:11 PM | quiverquant.comQJade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA NephropathyMay 29 at 4:05 PM | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 31 at 1:00 AM | InvestorPlace (Ad)Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term GainsMay 29 at 1:24 PM | uk.finance.yahoo.comJade Biosciences’ JADE101 Trial Opens a New Front in IgA Nephropathy InvestingMay 29 at 12:50 PM | tipranks.comJade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal ...May 26, 2026 | markets.businessinsider.comJade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal AntibodyMay 26, 2026 | globenewswire.comJade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA NephropathyMay 26, 2026 | globenewswire.comSee More Headlines JBIO Stock Analysis - Frequently Asked Questions How have JBIO shares performed this year? Jade Biosciences' stock was trading at $15.43 on January 1st, 2026. Since then, JBIO stock has increased by 36.4% and is now trading at $21.04. How were Jade Biosciences' earnings last quarter? Jade Biosciences, Inc. (NASDAQ:JBIO) issued its earnings results on Thursday, May, 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.05. Who are Jade Biosciences' major shareholders? Top institutional shareholders of Jade Biosciences include Janus Henderson Group PLC (6.29%), Affinity Asset Advisors LLC (1.30%), Orbimed Advisors LLC (0.37%) and Stempoint Capital LP (0.31%). How do I buy shares of Jade Biosciences? Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today5/31/2026Study update6/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 JBIO's financial health is in the Green zone, according to TradeSmith. JBIO has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JBIO Previous SymbolNASDAQ:JBIO CIK1798749 WebN/A Phone(617) 443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jade Biosciences$34.33 High Price Target$45.00 Low Price Target$16.00 Potential Upside/Downside+63.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-47.32% Debt Debt-to-Equity RatioN/A Current Ratio14.29 Quick Ratio14.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.01 per share Price / Book3.50Miscellaneous Outstanding Shares49,360,000Free Float37,978,000Market Cap$1.04 billion OptionableN/A Beta1.52 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:JBIO) was last updated on 5/31/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jade Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jade Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
